What single-treatment ACI actually means

For many patients referred for autologous chondrocyte implantation, the first difficult question is not whether the procedure will work — it is whether they truly need to go under general anaesthetic twice. Classic ACI, and its matrix-based successor MACI, is built around two entirely separate operations. At the first, the surgeon takes a small arthroscopic biopsy of healthy cartilage, typically from a low-load area of the knee. Those cells are then sent to a specialist laboratory, where they are expanded over several weeks before being returned in sufficient numbers for implantation. Only then is the second, open operation scheduled. NICE technology appraisal TA477 reflects this as the established UK standard, at an estimated cost of around £16,000 per patient.

STACI — Single-Treatment Autologous Chondrocyte Implantation — is a direct attempt to collapse that pathway into a single continuous sitting. Harvest, same-day processing, and implantation all occur within one operation, removing the laboratory expansion stage entirely. The biological rationale is sound: freshly harvested chondrocytes retain their native properties, and eliminating the wait removes a window in which the underlying defect can enlarge.

It is worth being clear about what STACI is not. Techniques such as AMIC (autologous matrix-induced chondrogenesis) and minced cartilage implantation are also single-stage, but neither relies on cultured chondrocytes — they work through marrow stimulation or mechanical fragmentation respectively. STACI sits in its own category: ACI-type cell biology, delivered without the two-stage delay. The concept has arrived; large-scale trial confirmation has not yet followed.

The case for doing it in one sitting

Three practical problems with the two-stage pathway help explain why single-treatment approaches are attracting serious clinical interest.

First, time works against the patient. A retrospective review of ACI and MACI cases found that delay between biopsy arthroscopy and second-stage implantation is an independent risk factor for expansion of the chondral defect — meaning the very lesion the surgeon plans to repair may be larger by the time it is treated. There is also evidence that a longer wait may negatively affect return to sport and broader clinical outcomes.

Second, a meaningful proportion of patients never reach the second stage at all. In one multi-surgeon series, only 26.1% of those who underwent a first-stage biopsy arthroscopy ultimately proceeded to a cartilage transplantation procedure. That figure does not imply STACI would achieve better results across the same population — many patients improved sufficiently after the first arthroscopy alone — but it does illustrate a genuine attrition gap between initiating treatment and completing it.

Third, the economics are striking in modelling terms. Health-economic analysis of single-stage cell-based cartilage repair estimated societal costs at approximately €11,800, compared with roughly €29,700 for standard two-stage ACI — a reduction of around 60%, driven almost entirely by removing the laboratory cell-expansion step. This is modelling rather than real-world pricing, but the direction of effect is consistent with what eliminating one theatre episode and several weeks of laboratory work would logically produce.

Underlying all three points is the simpler burden question: two general anaesthetics, two separate recovery periods, and a multi-week interval between them represent a significant disruption for working-age patients balancing employment, family, and rehabilitation commitments.

How STACI works biologically

During a STACI procedure, the surgeon takes a small arthroscopic sample of healthy cartilage — typically from a low-load zone of the joint — and processes it within the same theatre session. Rather than dispatching those cells to an external laboratory for expansion over several weeks, the processing happens immediately: the harvested tissue is disaggregated or minced to release chondrons, which are cartilage cells still enclosed within their native pericellular matrix. Those chondrons are then combined with a scaffold or membrane and placed directly into the defect during the same continuous operation.

The underlying biological premise is that freshly isolated chondrons, carrying their intact matrix coat, retain properties that weeks of ex-vivo culture may compromise. Taylor and Lee's 2019 paper — the conceptual anchor for STACI in the published literature — set out the rationale for this next-generation approach, arguing that eliminating the expansion phase could preserve cell viability while cutting the procedural timeline.

The most clinically developed programmes testing this principle are IMPACT (Europe) and RECLAIM (United States). Both combine the patient's own chondrons with allogeneic mesenchymal stem cells — donor cells, not the patient's own — in a single-stage construct. That distinction matters: this is not a purely autologous construct. The donor MSCs appear to act as signalling cells, stimulating the autologous chondrons rather than forming the tissue themselves. In the Phase I IMPACT trial, all patients showed statistically significant functional improvement at 12 months, with no treatment-related adverse events and histological evidence of hyaline-like regeneration containing type II collagen.

A separate in-vitro study found that non-passaged cartilage cells — as used in single-stage approaches — appear less susceptible to the pro-inflammatory cytokine TNFα than the passaged chondrocytes central to classic ACI, showing reduced IL-6 release under inflammatory conditions. This is laboratory data, not clinical outcome evidence, and should be read as a hypothesis-generating finding rather than a confirmed patient-level advantage.

What the evidence currently shows

The evidence base for STACI, assessed honestly, sits in early-phase territory. No large randomised controlled trial has been published under the STACI label, and the protocol has not been codified in NICE guidance or any major international cartilage-repair guideline. Patients who search for a formal regulatory approval signal — equivalent to NICE TA477's endorsement of two-stage ACI — will not find one for STACI.

The most clinically developed single-stage cell-based data comes from the IMPACT and RECLAIM programme. Phase I findings confirmed the procedure was safe over 12 months, with statistically significant improvements in knee function and durable pain reduction at extended follow-up. That is a meaningful early signal — but Phase I is designed to establish safety and feasibility, not to settle efficacy. Without a Phase II or III comparison against two-stage ACI, functional improvements at 12 months cannot be read as proof of equivalence or superiority.

The benchmark those gains would eventually need to approach is demanding. A Phase III trial of hydrogel-based two-stage ACI in 100 patients with defects between 4 and 12 cm² recorded KOOS scores rising from 39.8 to 84.7 over five years — a responder rate of 92.8% — with an overall treatment failure rate of just 1%. Single-stage ACI-type approaches have not yet been measured against that standard.

Long-term durability data — the five- to ten-year outcomes that would reassure clinicians about graft persistence and sustained function — are also absent for any single-stage ACI-type protocol. IMPACT's published follow-up extends to around 12 months; the tissue biology is promising, but what the repair looks like at a decade is currently unknown.

What would materially change this picture is Phase II and Phase III trial data. The RECLAIM programme in the United States represents the most active route toward that evidence, though no publication timeline has yet been confirmed in the sources available.

Which patients are suitable

Candidacy for any single-stage ACI-type procedure depends on a reasonably specific set of anatomical and clinical conditions — and being clear about those conditions is more useful to most patients than a general description of the technique.

The core requirement is a focal, full-thickness cartilage defect: a well-demarcated lesion, typically in the 2–4 cm² range, with healthy cartilage at its margins and an intact subchondral bone plate beneath it. The regenerative biology — whether single-stage or two-stage — depends on that contained architecture. If the defect is diffuse, or if the surrounding cartilage is itself worn, single-stage repair is unlikely to be recommended; the lesion that single-stage ACI targets is distinct from the generalised joint-surface deterioration of established osteoarthritis.

In terms of patient profile, younger and more active individuals with post-traumatic or osteochondral lesions tend to be the typical candidates. Degenerative wear across multiple compartments points toward different pathways entirely.

Prior marrow-stimulation surgery — microfracture, most commonly — is worth flagging as a meaningful part of the history. Cell-based repair is harder to achieve in a joint where the subchondral plate has already been drilled; this does not automatically exclude a patient, but it is a factor that affects planning.

Defect size also sets the outer boundary of current evidence. Classic two-stage ACI has Phase III trial data for defects up to 12 cm²; STACI protocols have been evaluated primarily at the 2–4 cm² end of that range, and candidacy for larger lesions is not yet established.

Determining whether these criteria are met — through MRI, clinical examination, and a detailed history — is the work of a thorough specialist assessment rather than a self-referral checklist.

Where STACI sits among single-stage cartilage options

The single-stage cartilage landscape already contains well-established options, and understanding how STACI relates to them matters. AMIC — microfracture augmented with a collagen membrane — stimulates marrow-derived progenitor cells in a single theatre session; it does not use cultured chondrocytes. Minced cartilage implantation (MCI) mechanically redistributes fragmented autologous tissue without any cell culture step. In a 2024 matched cohort of 48 patients with a mean defect size of approximately 2.5 cm², AMIC outperformed MCI on VAS pain (p=0.004), Lysholm score (92% vs 64% positive responders, p=0.043), and KOOS quality of life at two to four years. OATS and mosaicplasty transplant intact osteochondral plugs carrying genuine hyaline cartilage, with long-term randomised evidence behind them, though donor-site morbidity is a real consideration — and the technique is best suited to defects typically between 1 and 2 cm² (mosaicplasty extending to around 4 cm²).

STACI's ambition is to fill the gap between AMIC and full two-stage ACI: the cell biology of ACI, without the staging burden. That is a coherent and clinically meaningful aim. Whether it has yet been achieved in the evidence is a harder question. The IMPACT programme — the most developed single-stage cell-based analogue — has Phase I safety data and 12-month functional outcomes; AMIC has comparative cohort studies; OATS has decade-long randomised follow-up. STACI's biology is promising, but it has not yet accumulated the evidence that would place it alongside those established options.

What would change that picture is Phase II and Phase III data, with follow-up beyond five years. Until those results are available, STACI remains a technique to be considered selectively — and the selection depends on a thorough specialist assessment of defect size, tissue quality, prior surgery, and activity goals. That kind of assessment, weighing which single-stage or staged pathway is appropriate for a specific patient, is what Professor Paul Y. F. Lee undertakes at the London Cartilage Clinic for patients seeking advanced cartilage restoration in London.

1. [1] Treatment of Large Cartilage Defects in the Knee by Hydrogel-Based ACI: 5-Year Follow-Up Phase III Trial. (2025). https://doi.org/10.1177/19476035251334737 https://doi.org/10.1177/19476035251334737
2. [2] From IMPACT to RECLAIM: A Single-Stage Cell Therapy for Articular Cartilage Repair and a Platform for Musculoskeletal Tissue Regeneration. (2025). https://doi.org/10.1007/s12178-025-09949-8 https://doi.org/10.1007/s12178-025-09949-8
3. [3] Allogeneic Mesenchymal Stem Cells Stimulate Cartilage Regeneration and Are Safe for Single-Stage Cartilage Repair in Humans upon Mixture with Recycled Autologous Chondrons. (2017). https://doi.org/10.1002/stem.2475 https://doi.org/10.1002/stem.2475
4. [4] Evaluating single-stage cartilage treatments in the knee: A systematic review and meta-analysis of OATS and minced cartilage repair. (2026). https://doi.org/10.1016/j.jor.2025.12.052 https://doi.org/10.1016/j.jor.2025.12.052
5. [5] Autologous matrix-induced chondrogenesis provides better outcomes than autologous minced cartilage implantation. (2024). https://doi.org/10.1002/ksa.12387 https://doi.org/10.1002/ksa.12387
6. [6] Early health economic modelling of single-stage cartilage repair. (2017). https://doi.org/10.1002/term.2197 https://doi.org/10.1002/term.2197
7. [7] Poster 288: Effect of Time Delay From Biopsy to Second-Stage Implantation on Return to Sport and Clinical Outcomes following ACI. (2023). https://doi.org/10.1177/2325967123S00264 https://doi.org/10.1177/2325967123S00264
8. [8] Comparison of Minced Cartilage Implantation with Autologous Chondrocyte Transplantation in an In Vitro Inflammation Model. (2024). https://doi.org/10.3390/cells13060546 https://doi.org/10.3390/cells13060546